Ergoteles’s Advent Technologies ADN Stock Holding History

Ergoteles’s Portfolio ADN Stock Details ADN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,821	Closed	-$213K	–	1503
2022 Q2	$213K	Buy	2,821 +181	+7%	+$10.9K	0.01%	1290
2022 Q1	$184K	Buy	+2,640	New	+$299K	0.01%	1022

Other funds holding ADN

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PSCM

Prince Street Capital Management New York $40.3M AUM 0.66% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Ergoteles's ADN Position: Q3 2022 in Review

Ergoteles sold out of Advent Technologies (ADN) in Q3 2022, closing a stake of 2,821 shares — an estimated $213K sold.

Ergoteles first reported a position in ADN in Q1 2022 and held it in 2 quarters. The position peaked at $213K in Q2 2022. 44 funds tracked by Wall St. Rank hold ADN as of Q3 2022.

Ergoteles reported no remaining Advent Technologies position as of Q3 2022 after selling out during the quarter.
Ergoteles sold 2,821 Advent Technologies shares in Q3 2022, an estimated $213K.
Ergoteles first reported a position in Advent Technologies in Q1 2022 and held it in 2 quarters.
Ergoteles's Advent Technologies position peaked at $213K in Q2 2022.
44 funds tracked by Wall St. Rank held Advent Technologies as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.